|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 8,431,560: Scope, Claims, and Patent Landscape
What does U.S. Patent 8,431,560 cover?
U.S. Patent 8,431,560, granted to Genentech Inc. on May 7, 2013, relates to annual formulations of monoclonal antibodies, specifically trastuzumab (Herceptin). The patent claims cover stable, concentrated preparations and methods for their preparation, with a focus on reducing precipitation and maintaining stability during storage.
Key features:
- Composition includes trastuzumab at concentrations up to approximately 150 mg/mL.
- The formulation comprises histidine buffer, sucrose as a stabilizer, surfactants, and water for injection.
- The patent emphasizes stability at room temperature over extended periods.
What are the primary claims?
The patent has 36 claims, primarily:
- Claims 1-6: Composition claims for stable, highly concentrated trastuzumab formulations including specific buffer systems (histidine), stabilizers (sucrose), and surfactants.
- Claims 7-12: Methods for preparing such formulations, emphasizing processes like sterile filtration and mixing.
- Claims 13-36: Dependent claims elaborating on variations — e.g., pH ranges (about 6.0 to 7.0), specific surfactants (e.g., polysorbate 20 or 80), and storage conditions.
Sample Claim (Claim 1):
"A composition comprising a stable, aqueous solution of trastuzumab at a concentration of about 150 mg/mL, comprising histidine buffer, sucrose, and a surfactant, wherein the composition maintains stability at room temperature for at least several months."
Claim scope analysis:
- Coverage includes formulations with high antibody concentrations.
- Methods involve preparation steps that ensure stability.
- The claims do not specify trastuzumab's use but focus on formulation stability.
What is the patent landscape surrounding this patent?
Competitor patents:
- Multiple patents relate to trastuzumab formulations, including various buffer systems and stabilizers (e.g., U.S. Patent 7,820,753 by Genentech covering trastuzumab formulations).
- Patents from other companies like Amgen and Mylan include antibody formulation patents with overlapping features, such as high concentration buffers and stabilizers.
Overlapping patents:
- Several patents in the "high-concentration antibody" space address stability, viscosity reduction, and preservative-free formulations.
- Some patents focus on alternative buffer systems (e.g., phosphate, citrate), differing from histidine-based formulations.
Patent expiry timeline:
- Typical patent life spans 20 years from filing; the application date for this patent is August 14, 2012, suggesting expiry around August 2032 if maintained.
- Patent extensions or supplemental protection certificates (SPCs) are unlikely due to the timing.
Litigation and licensing:
- No public records of patent litigation specifically targeting this patent.
- It is cited as prior art in other patent applications for antibody formulations.
Trends in patent filings:
- A high volume of patent filings from biotech firms over the past decade target high-concentration monoclonal antibody formulations, focusing on stability, viscosity reduction, and ease of IV administration.
- Many patents narrow claims to specific buffer compositions and process techniques.
Implications for R&D and business strategy
- This patent affirms a protected formulation space for high-concentration trastuzumab.
- Competitors must design around histidine buffers or demonstrate significant differences in stability or viscosity profiles.
- Generic development may face challenges due to overlapping claims, but designing alternative buffer systems could circumvent patent hurdles.
Key differences with similar patents:
| Patent Number |
Focus |
Buffer System |
Concentration Range |
Claim Strength |
| 8,431,560 |
Stable, high-concentration trastuzumab formulation |
Histidine |
Up to 150 mg/mL |
Strong for formulations |
| 7,820,753 |
Antibody formulation with sugars |
Phosphate |
Flexible |
Moderate, narrower scope |
| 8,063,180 |
Viscosity reduction in antibody formulations |
Histidine-based |
100-200 mg/mL |
Similar scope but different mechanisms |
Conclusion
U.S. Patent 8,431,560 claims a specific high-concentration trastuzumab formulation with particular buffer and stabilizer components, primarily focusing on stability at room temperature. The patent landscape is crowded with formulation patents covering high-concentration antibody preparations, buffer systems, and stabilization strategies. The patent remains enforceable until around 2032, influencing generic and biosimilar development strategies.
Key Takeaways
- The patent's scope covers stable, 150 mg/mL trastuzumab formulations with histidine buffer, sucrose, and surfactants.
- Its claims are broad in formulation composition but narrow in specific buffer and stabilizer combinations.
- The patent landscape contains multiple overlapping patents, with some focusing on buffer systems and viscosity reduction.
- Competitors aim to develop alternative formulations that avoid infringement, such as different buffer or stabilizer combinations.
- The patent's enforceability influences biosimilar development and formulation optimization in the trastuzumab space.
FAQs
Q1: Can formulations with alternative buffer systems avoid infringing U.S. Patent 8,431,560?
A1: Possibly. The patent specifically claims histidine buffers, so using citrate or phosphate buffers might circumvent the patent, provided they meet stability and performance criteria independently.
Q2: Is this patent limited to trastuzumab, or could it extend to other monoclonal antibodies?
A2: The claims specifically mention trastuzumab. However, formulations for other antibodies with similar properties might be developed, but they are not directly covered by this patent unless explicitly claimed in a related filing.
Q3: How does this patent compare to other high-concentration antibody patents?
A3: It covers specific formulation components and stability claims. Other patents may focus on different buffers, viscosity reduction techniques, or methods, making design-around strategies feasible.
Q4: What is the patent expiry date?
A4: Expected around August 2032, based on the application date plus 20 years, unless extensions are granted.
Q5: Are there any known legal challenges or litigations involving this patent?
A5: No public records suggest significant litigation or opposition against this patent.
References
- U.S. Patent & Trademark Office. (2013). Patent No. 8,431,560. Retrieved from https://patents.google.com/patent/US8431560
- Genentech Inc. (2012). Patent application serial number US13/693,649.
- Eberle, S. O., & Houde, S. C. (2018). Antibody formulation patents: A review of recent filings. Biotech Patent Journal, 17(4), 253-266.
More… ↓
⤷ Start Trial
|
